Ledraxen (Enoxaparin Sodium)

Ledraxen, a low molecular weight heparin, is used in clinical settings that require inhibition of clot formation.

• Deep vein thrombosis (DVT) prophylaxis: prevents clot development in patients undergoing surgery or immobilization.
• Pulmonary embolism treatment: facilitates resolution of existing emboli and reduces recurrence risk.
• Anticoagulation during hemodialysis: maintains circuit patency by preventing thrombus formation.

• Enoxaparin sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This selective blockade reduces thrombin generation and fibrin clot formation, providing anticoagulant activity with a more predictable dose‑response compared with unfractionated heparin. The enhanced antithrombin activity leads to a rapid onset of action after subcutaneous injection, and the drug’s low plasma protein binding contributes to a longer half‑life than unfractionated heparin, allowing once‑ or twice‑daily dosing in many protocols.

Enoxaparin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site bruising or hematoma: localized bleeding under the skin.
• Minor bleeding: such as epistaxis, gum bleeding, or easy bruising.
• Nausea or vomiting: gastrointestinal discomfort.
• Headache or dizziness: transient neurologic symptoms.
• Elevated liver enzymes: mild, transient hepatic changes.

Serious or Rare Side Effects

• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clot risk.
• Major hemorrhage: internal bleeding that may be life‑threatening.
• Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.
• Severe allergic reaction: anaphylaxis or angioedema.
• Thrombosis despite therapy: rare clot formation while on treatment.

Before initiating Ledraxen, clinicians should evaluate several safety considerations to minimize bleeding risk and other complications.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function.
• Surgery or invasive procedures: discontinue before to reduce peri‑operative bleeding.
• Concomitant antiplatelet therapy: increase monitoring for additive bleeding.
• Pregnancy: use only if potential benefit justifies potential risk to the fetus.
• History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin can interact with other medicines, affecting its anticoagulant effect or increasing bleeding potential.

Major Interactions (Avoid)

• Other therapeutic anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulation may cause severe bleeding.
• Systemic thrombolytics (e.g., alteplase): heightened risk of major hemorrhage.
• High‑dose NSAIDs or aspirin: potentiate gastrointestinal and systemic bleeding.
• Neuraxial anesthesia or spinal puncture: increased chance of spinal hematoma.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., clopidogrel, ticagrelor): monitor for bleeding signs.
• Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: may modestly raise bleeding risk.
• Renally cleared drugs that affect coagulation (e.g., certain antibiotics): observe anti‑Xa activity.